Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in High-risk Prostate Cancer Post-Prostatectomy
NCT01927627Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by Case Comprehensive Cancer Center. Started Nov 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01927627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01927627.